Drug reference
amivantamab
Bivalent antibody
Bivalent antibody
CDSCO approved
EXCRETION
—
not curated
INTERACTIONS
—
none in our sources
PREGNANCY
—
not curated
Mechanism
Targets both EGFR and c-MET. It downregulates oncogenic signaling via these receptors, causes their heterodimerization and internalization, promotes NK cell-mediated cellular toxicity of the cancer cell, and promotes macrophage-mediated trogocytosis.
Indications
EGFR-mutated non-small cell lung cancer (NSCLC)locally advanced or metastatic NSCLC with EGFR exon 20 insertion mutations
Side effects
Common
dermatological reactions
Serious
- pneumonitis
- ocular toxicity
Related guidelines
Ask House about amivantamab
Continue into a citation-backed clinical answer with the drug context already attached.
Sources: Goodman & Gilman 14e·Verified: 2026-05-10 · House clinical team